← Back to patent-cliff list
CAS 138402-05-8
2-butyl-1,3-diazaspiro[4.4]non-1-en-4-one
Codes: IRBE-003, SPAR-008
Application context (from source-drug indications)
HypertensionAtorvastatin Calcium Hydrate/IrbesartanHyperlipidaemiaAtorvastatin Calcium Hydrate/IrbesartanHypertensionIrbesartan/TrichlormethiazideOesophageal diseaseIrbesartanHypertensionIrbesartanDiabetic nephropathyIrbesartanHypercholesterolaemiaIrbesartanAlbuminuriaIrbesartanType 2 diabetesIrbesartan局灶性节段性肾小球硬化症Sparsentan免疫球蛋白a肾病Sparsentan抗中性粒细胞胞浆抗体相关性血管炎SparsentanKidney diseaseSparsentanAlport 综合征Sparsentan过敏性紫癜Sparsentan
Source drugs (routes using this intermediate)
| Drug | Tier | Expiry |
|---|---|---|
| Atorvastatin Calcium Hydrate/Irbesartan | Tier C — Watch / trade | - |
| Irbesartan/Trichlormethiazide | Tier C — Watch / trade | - |
| Irbesartan | Tier B — Position early | - |
| Sparsentan | Tier C — Watch / trade | - |
Position in synthesis routes (up/downstream chain)
Ordered by route registration; left → right is the synthesis direction. The highlighted node is the current CAS; others link to their own profiles.
ethyl 1-aminocyclopentane-1-carboxylate→ethyl pentanimidate→2-butyl-1,3-diazaspiro[4.4]non-1-en-4-one→4'-(bromomethyl)-[1,1'-biphenyl]-2-carbonitrile→4'-((2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl)-[1,1'-biphenyl]-2-carbonitrile→2-(2-methoxyphenyl)-4,4-dimethyl-4,5-dihydrooxazole→p-tolylmagnesium bromide→4,4-dimethyl-2-(4'-methyl-[1,1'-biphenyl]-2-yl)-4,5-dihydrooxazole→4'-methyl-[1,1'-biphenyl]-2-carbonitrile
ethyl 1-aminocyclopentane-1-carboxylate→ethyl pentanimidate→2-butyl-1,3-diazaspiro[4.4]non-1-en-4-one→4'-(bromomethyl)-[1,1'-biphenyl]-2-carbonitrile→4'-((2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl)-[1,1'-biphenyl]-2-carbonitrile→2-(2-methoxyphenyl)-4,4-dimethyl-4,5-dihydrooxazole→p-tolylmagnesium bromide→4,4-dimethyl-2-(4'-methyl-[1,1'-biphenyl]-2-yl)-4,5-dihydrooxazole→4'-methyl-[1,1'-biphenyl]-2-carbonitrile
ethyl 1-aminocyclopentane-1-carboxylate→ethyl pentanimidate→2-butyl-1,3-diazaspiro[4.4]non-1-en-4-one→4'-(bromomethyl)-[1,1'-biphenyl]-2-carbonitrile→4'-((2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl)-[1,1'-biphenyl]-2-carbonitrile→2-(2-methoxyphenyl)-4,4-dimethyl-4,5-dihydrooxazole→p-tolylmagnesium bromide→4,4-dimethyl-2-(4'-methyl-[1,1'-biphenyl]-2-yl)-4,5-dihydrooxazole→4'-methyl-[1,1'-biphenyl]-2-carbonitrile
ethyl 4-bromo-3-methylbenzoate→ethyl 4-bromo-3-(bromomethyl)benzoate→ethyl 4-bromo-3-(ethoxymethyl)benzoate→(2-(N-(4,5-dimethylisoxazol-3-yl)-N-(methoxymethyl)sulfamoyl)phenyl)boronic acid→ethyl 2'-(N-(4,5-dimethylisoxazol-3-yl)-N-(methoxymethyl)sulfamoyl)-2-(ethoxymethyl)-[1,1'-biphenyl]-4-carboxylate→N-(4,5-dimethylisoxazol-3-yl)-2'-(ethoxymethyl)-4'-(hydroxymethyl)-N-(methoxymethyl)-[1,1'-biphenyl]-2-sulfonamide→4'-(bromomethyl)-N-(4,5-dimethylisoxazol-3-yl)-2'-(ethoxymethyl)-N-(methoxymethyl)-[1,1'-biphenyl]-2-sulfonamide→2-butyl-1,3-diazaspiro[4.4]non-1-en-4-one→4'-((2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl)-N-(4,5-dimethylisoxazol-3-yl)-2'-(ethoxymethyl)-N-(methoxymethyl)-[1,1'-biphenyl]-2-sulfonamide
ethyl 4-bromo-3-(ethoxymethyl)benzoate→2-butyl-1,3-diazaspiro[4.4]non-1-en-4-one→(4-bromo-3-(ethoxymethyl)phenyl)methanol→4-bromo-3-(ethoxymethyl)benzyl methanesulfonate→3-(4-bromo-3-(ethoxymethyl)benzyl)-2-butyl-1,3-diazaspiro[4.4]non-1-en-4-one dioxalate→N-(4,5-dimethylisoxazol-3-yl)-N-(methoxymethyl)-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzenesulfonamide
2-butyl-1,3-diazaspiro[4.4]non-1-en-4-one→1-bromo-2,4-dimethylbenzene→isopropyl 2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzenesulfonate→isopropyl 2',4'-dimethyl-[1,1'-biphenyl]-2-sulfonate→2',4'-dimethyl-[1,1'-biphenyl]-2-sulfonic acid→9-(bromomethyl)-7H-dibenzo[c,e][1,2]oxathiepine 5,5-dioxide→4'-(bromomethyl)-2'-(ethoxymethyl)-[1,1'-biphenyl]-2-sulfonic acid→4'-((2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl)-2'-(ethoxymethyl)-[1,1'-biphenyl]-2-sulfonic acid→4'-((2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl)-2'-(ethoxymethyl)-[1,1'-biphenyl]-2-sulfonyl chloride→4,5-dimethylisoxazol-3-amine
Intermediates available on this site
Side-by-side comparison of all listed offers on this CAS; price bands are list-price ranges, final price subject to RFQ confirmation.
| Supplier | Product | Price band | MOQ | Lead time | Qualifications | Action |
|---|---|---|---|---|---|---|
| Qualified Partner — East China API Works | (2-(N-(4,5-dimethylisoxazol-3-yl)-N-(methoxymethyl)sulfamoyl)phenyl)boronic acid Pharmaceutical Intermediates | On request | On request | On request | — | |
| Unibest Nantong cGMP Site | N-(4,5-dimethylisoxazol-3-yl)-N-(methoxymethyl)-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzenesulfonamide Pharmaceutical Intermediates | On request | On request | On request | — | |
| Unibest Taizhou GMP-like Site | 4-bromo-3-(ethoxymethyl)benzaldehyde Pharmaceutical Intermediates | On request | On request | On request | — | |
| Qualified Partner — East China API Works | 4-bromo-3-ethoxymethyl-benzoic acid ethyl ester Pharmaceutical Intermediates | On request | On request | On request | — | |
| Unibest Nantong cGMP Site | N-(4,5-Dimethyl-3-isoxazolyl)-2'-(ethoxymethyl)-4'-formyl-N-(methoxymethyl)[1,1'-biphenyl]-2-sulfonamide Pharmaceutical Intermediates | On request | On request | On request | — | |
| Unibest Taizhou GMP-like Site | N-(4,5-dimethylisoxazol-3-yl)-2'-(ethoxymethyl)-4'-(hydroxymethyl)-N-(methoxymethyl)-[1,1'-biphenyl]-2-sulfonamide Pharmaceutical Intermediates | On request | On request | On request | — |
This is a CAS-level registry record: registrations across routes are merged. Supplier offers and buyer demands will be matched on this CAS as the primary key.